The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new Women’s Health Programme. The initiative aims to improve evidence on medicines and medical devices, focusing on how their risks and benefits may differ for women.
Women have historically been underrepresented in clinical research, leading to gaps in understanding for conditions specific to women, or those that present differently or disproportionately in them. An MHRA analysis of 4,616 UK clinical trial applications from 2019 to 2023 showed that pregnant women were included in 1.1% of trials, and breastfeeding women in 0.6%.
Women’s Health Minister, Baroness Gillian Merron, stated that for too long, women’s health has been overlooked. She added that the programme, alongside the renewed Women’s Health Strategy, will lead to better evidence, treatments, and a health system that works for women.
Lawrence Tallon, MHRA Chief Executive, noted that closing these evidence gaps is a significant opportunity. He said better evidence can help tailor healthcare more effectively to women's needs. The programme will involve patients, researchers, healthcare professionals, and industry to strengthen available evidence.